This episode marks the end of “Lab Medicine Rounds.” Host Justin Kreuter, M.D., reflects on the impact of the series and introduces an upcoming video-based[...]

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss summertime illnesses and key insights from a recent diagnostic investment event.

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

John Lieske, M.D., explains why it's now easier for clinicians to pull information from Mayo Clinic Laboratories' supersaturation test report. An updated format summarizes complex information to help guide the treatment of kidney stones.

This week's research roundup feature: Emergence of inducible macrolide resistance in mycobacterium chelonae due to broad-host-range plasmid and chromosomal variants of the novel 23S rRNA methylase gene, erm(55).

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest update on the U.S. Food and Drug Administration’s (FDA) proposed rule to oversee laboratory-developed tests (LDTs) and what that could mean for laboratories.

This week's research roundup feature: SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients.

Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment and family screening.

Due to the upcoming Independence Day holiday on Tuesday, July 4, Mayo Clinic Laboratories' sample pickup and delivery schedules will be altered. To ensure sample viability and minimize test turnaround time delays, we have implemented several adjustments and guidelines.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to talk about the evolution of remote diagnostics and how Mayo Clinic’s remote cardiovascular monitoring services empower physicians and patients.

The spectrum of autoimmune movement disorders, diagnosis and treatment.

In 2010, Jessica Balcom began her career with Mayo Clinic supporting molecular testing in the Department of Laboratory Medicine and Pathology with a joint appointment in the Mayo Clinic Cystic Fibrosis Center. Now she serves as a hematology-oncology genetic counselor supervisor managing a large team of genetic counselors, assistants, and a clinical variant scientist who help guide appropriate utilization of genetic testing.

Mayo Clinic Laboratories’ new MayoComplete Lung Cancer Panel (Mayo ID: MCLNG) provides more information than single-gene assays and faster results than a comprehensive solid tumor panel that covers hundreds of genes.

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.

This week's research roundup feature: Career decisions, training priorities, and perceived challenges for anesthesiology residents in the United States.